“Non Classical” (CCR2+ CD16++ CD14+ MHC Class II+ CD209+) subset of mouse monocytes were expanded using NOD2 small-molecule activators. CCR2 enabled these cells to infiltrate tumors and inhibit metastasis in mouse models of colon, lung, breast and melanoma through CCL6 recruitment of NK cells. The monocyte CCR2/CCL2 axis merits further investigation for cancer intervention! “Inducible […]

Levels of LTbR (Lymphotoxin beta Recpeptor) on TAM (Tumor Associated Macrophage) inversely correlate with anti-tumor response, indicating an immunosuppresive role. This Chinese research group demonstrate that disrupting this expression in mice by silencing or knockout causes tumor regression in a mouse lung carcinoma model. “LTBR acts as a novel immune checkpoint of tumor-associated macrophages for

This Korean research group screened mAbs generated against Multiple Myeloma and developed a mAb (clone NPB15) specific to an epitope of CD98 present on stem and cancer cells, but not on CD98 presented by more differentiated tissues. They demonstrated the therapeutic potential of this mAb. “A monoclonal antibody recognizing CD98 on human embryonic stem cells

“Cyclophilin A is a ligand for RAGE in thrombo-inflammation” P Seizer, D Heinzmann, et al. Cardiovascular Research (2024) 120: 385-402. https://doi.org/10.1093/cvr/cvad189 PMID: 38175781 Ancell anti-CD147 antibody (clone UM-8D6) was used to block monocyte chemotaxis, induce NfkB translocation and to stimulate MyD88 antigen upregulation in monocytes. Ancell anti-CD147 mAb products

“Generation of an Inhibitory NK Cell Subset by TGF-β1/IL-15 Polarization” DC Chung, PS Ohashi, et al. J Immunol(2024) 212(12): 1904-1912. https://doi.org/10.4049/jimmunol.2300834 PMID: 38668728 This Toronto based research group used a combination of TGF-b1 and IL-15 to induce a CD103+/CD49a+ phenotype in peripheral blood derived NK cells. Co incubation with this NK cell line inhibited CD4

Ancell mAbs were used by this Cal State Research group to block trogocytic killing of Triconomas Vaginelas parasite by human PLB-95 Neutrophil-Like-cells in vitro. Blocking CD11c and CD18 receptors on NLC with antibodies resulted in significant reduction of killing, implicting CR3 mediated complement fixation as the primary mechanism. “Complement receptor 3 is required for maximum

Russian Researchers investigating Redox processes in Neutrophil activation. “Redox processes are major regulators of leukotriene synthesis in neutrophils exposed to bacteria Salmonella typhimurium; the way to manipulate neutrophil swarming” E A Golenkina, G F Sud’ina, et al. (Feb 2024) Front. Immunol 15 (06 February 2024) PMID: 38384456 PMCID: PMC10880102 DOI: 10.3389/fimmu.2024.1295150 . Relevant Ancell Products

Researchers investigating the role of Siglec-5 in Neutrophil activation. “SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity” P Bouti, HL Matlung et al. (Dec 2023) Int J Mol Sci 24(24): 17141. https://doi.org/10.3390/ijms242417141 Relevant Ancell Products anti-human CD18 products anti-human CD11b products anti-human CD47 products Recombinant human CD54-muIg

Acute Coronary Syndrome(ACS) was simulated by provoking healthy PBMC with autoimmune self antigen pepetide LL-37. Effect of blockade on HLA Class I, Class II, PD-1 and CTLA-4 on T cell expression of Activation Induced Molecules (AIM) was then examined. “Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome” Chernomordik F, PC Dermayuga, et al.

“Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences” Marelia Barreca, et al. Explor Target Antitumor Ther. 2022; 3(6): 763–794. Published online 2022 Dec 26. doi: 10.37349/etat.2022.00112 PMID: 36654819 Relevant Ancell Research Products anti-human CD269(BCMA) mAb human CD269(BCMA) Recombinant Protein anti-human CD22 mAb anti-human CD79b anti-CD19 mAb